#Canada #FDA Approval #Toronto #Perimeter Medical #Imaging AI

Perimeter Medical Imaging AI Reports Robust Third Quarter 2025 Financial Performance

Perimeter Medical Imaging AI, a leading company in the medical imaging sector, has released its financial results for the third quarter of 2025, showcasing a remarkable performance. As the company eagerly awaits the FDA's decision regarding its Premarket Approval (PMA) application for the anticipated Perimeter B-Series device, commercial traction seems to be gaining momentum, particularly with their current S-Series technology.

Financial Highlights

For the third quarter of 2025, Perimeter announced revenues of $536,000, marking a 157% increase year-over-year compared to Q3 2024. This growth is a strong confirmation of the company’s effective market strategies and the increasing demand for its imaging solutions. Notably, the first nine months of 2025 have recorded revenues amounting to $1.6 million, an impressive 88% rise over the entire revenue garnered in 2024.

Additionally, Perimeter's commitment to cost management has been evident, as operating expenses for Q3 2025 decreased by 34% compared to the same quarter in the previous year and 30% sequentially from Q2 2025. This has resulted in a marked improvement in net loss, now sitting at approximately $2.7 million, a significant reduction from the $4.7 million reported in Q3 2024.

Clinical Adoption and Strategic Initiatives

The company’s S-Series OCT (Optical Coherence Tomography) devices continue to gain traction across multiple leading medical centers. Surgeons have utilized the S-Series in imaging more than 3,500 patients so far, a 17% increase from the previous report. This growing clinical application emphasizes the technology’s importance in enhancing surgical practices and patient care.

In September, Dr. Amelia Tower, a notable breast surgical oncologist, presented the capabilities of the S-Series during the 2025 Annual Clinical Assembly of the American College of Osteopathic Surgeons. This gathering, which attracts over 1,200 surgeons annually, provided a platform to spotlight the vital role of Perimeter's technology in improving surgical outcomes, particularly in breast conservation surgeries.

Future Prospects with the B-Series

As anticipation builds for the upcoming Perimeter B-Series OCT integrated with ImgAssist AI, the company remains optimistic regarding regulatory approvals, expecting a decision from the FDA in the first half of 2026. The B-Series aims to introduce ground-breaking advancements in cancer surgery, leveraging AI to enhance procedural precision and patient outcomes.

Additionally, Perimeter has launched the OCT-Tissue Surveillance Registry. This new database is designed to accumulate extensive imaging and procedural data to refine and enhance future product developments, including continuous improvements to their AI deep-learning model.

In a strategic move, Perimeter appointed Dr. Ted James as the Chief Medical Officer, whose extensive experience will bolster the company’s growth trajectory as they steer the B-Series toward commercialization.

Corporate Developments

The third quarter also highlighted several corporate accomplishments, including the closing of a prospectus offering which provided gross proceeds of approximately $1.6 million. Perimeter made significant leadership appointments to drive sales growth and established the Perimeter Industry Advisory Board to guide their strategic initiatives across various channels and markets.

Conclusion

In conclusion, Perimeter Medical Imaging AI’s third-quarter results reflect not only a robust current business model but also a promising future in transforming cancer surgery through advanced imaging technology. With key regulatory milestones on the horizon and a committed leadership team, the company is well-positioned to capitalize on its growth trajectory and enhance surgical care nationwide.